Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

31.97
+0.05000.16%
Volume:86.22K
Turnover:2.75M
Market Cap:1.90B
PE:-4.56
High:32.12
Open:31.85
Low:31.54
Close:31.92
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:0.55
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.85
PE(LYR):-4.49

Loading ...

Agios Pharmaceuticals Q2 Product Revenue USD 44.745 Million Vs. IBES Estimate USD 25.5 Million

Reuters
·
Jul 30

U.S. Research ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics

Reuters
·
Jul 27

Agios Pharmaceuticals Inc : Leerink Partners Raises Target Price to $62 from $59

THOMSON REUTERS
·
Jul 27

U.S. Stocks on the Move-duke Robotics, Tesla, Hasbro

Reuters
·
Jul 22

Agios Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 21

Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright

TIPRANKS
·
Jul 21

U.S. Stocks on the Move-utz Brands, Tutor Perini, Tripadvisor

Reuters
·
Jul 21

U.S. Stocks on the Move-3m, Gold Miners, Hasbro

Reuters
·
Jul 21

Top Premarket Decliners

MT Newswires Live
·
Jul 21

Agios Falls After Scrapping Experimental Sickle Cell Disease Drug

Reuters
·
Jul 21

Agios Pharmaceuticals Shares Down 12.6% Premarket as it Discontinues Sickle Cell Disease Drug Development

THOMSON REUTERS
·
Jul 21

Agios Pharma to Discontinue Sickle Cell Disease Treatment Development

Reuters
·
Jul 21

Agios Posts Phase 2 Tebapivat Sickle Cell Trial Update Press Release

Reuters
·
Jul 21

Agios Pharmaceuticals - Will not Advance Tebapivat in Sickle Cell Disease

THOMSON REUTERS
·
Jul 21

Agios Pharmaceuticals - FDA Priority Review for Mitapivat in Sickle Cell Disease; Pdufa Date November 1, 2026

THOMSON REUTERS
·
Jul 21

Agios Pharmaceuticals - Tebapivat Safety Consistent with Prior Sickle Cell Disease Trials

THOMSON REUTERS
·
Jul 21

Agios Pharmaceuticals - Primary Endpoint Achieved by up to 47.1% in Tebapivat Arms; 33.3% in Placebo Arm

THOMSON REUTERS
·
Jul 21

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

THOMSON REUTERS
·
Jul 21

The Bull Case For Agios Pharmaceuticals (AGIO) Could Change Following FDA Priority Review For Mitapivat In Sickle Cell

Simply Wall St.
·
Jul 19

H.C. Wainwright Remains a Buy on Agios Pharma (AGIO)

TIPRANKS
·
Jul 13